Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Up 47.1% in December

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a large increase in short interest in December. As of December 31st, there was short interest totaling 212,833 shares, an increase of 47.1% from the December 15th total of 144,691 shares. Currently, 2.0% of the company’s stock are sold short. Based on an average trading volume of 345,914 shares, the short-interest ratio is presently 0.6 days. Based on an average trading volume of 345,914 shares, the short-interest ratio is presently 0.6 days. Currently, 2.0% of the company’s stock are sold short.

Azitra Stock Performance

Azitra stock traded down $0.02 during mid-day trading on Friday, reaching $0.33. The company’s stock had a trading volume of 4,260,324 shares, compared to its average volume of 879,012. Azitra has a twelve month low of $0.26 and a twelve month high of $3.92. The business has a 50 day moving average price of $0.33 and a 200-day moving average price of $0.74.

Azitra (NYSEAMERICAN:AZTR) last issued its earnings results on Wednesday, November 12th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.12. Research analysts expect that Azitra will post -2.78 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Maxim Group cut their target price on shares of Azitra from $13.32 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, September 24th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $4.00.

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.